The agreement will come into effect on July 1, 2026, and will remain valid for 7.5 years. It also includes an option to extend the contract by a further three years with the mutual consent of both parties.
The company said the agreement covers the exclusive supply of OTC medicines under the terms of the contract. It also clarified that neither its promoters, the promoter group nor group companies have any interest in the entity awarding the contract.The latest order comes weeks after Sai Parenterals announced that it had secured a $11 million (around ₹104.5 crore) purchase order from PILL CORP in Bulacan, Philippines, for the exclusive supply of anti-tuberculosis (TB) medicines over a 10-year period. The company had said purchase orders would be released periodically throughout the tenure of the agreement.
In its March quarter earnings, Sai Parenterals also outlined an ambitious capital expenditure programme aimed at expanding manufacturing capacity, upgrading its existing facilities, setting up a greenfield pharmaceutical plant in Australia and establishing a dedicated research and development (R&D) centre. The company expects all these projects to be completed by FY27.
As part of the expansion plan, Sai Parenterals is investing ₹118 crore to enhance capacity and upgrade its Indian manufacturing facilities to EU-GMP standards, supporting complex injectable formulations, contract development and manufacturing (CDMO) opportunities, and exports to regulated markets.
Shares of Sai Parenterals Ltd. ended 4.93% higher at ₹617.35 on the NSE on Wednesday, ahead of the company’s announcement.
